Volume 21 Issue 11
Nov.  2023
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2023  >  21(11): 1849-1851
ZHAO Hao, QI Xueyuan, WANG Junbin, ZHANG Xiaofeng, TAO Lu, YU Liang. Expression and significance of peripheral blood lymphocyte subsets in non-small cell lung cancer[J]. Chinese Journal of General Practice, 2023, 21(11): 1849-1851. doi: 10.16766/j.cnki.issn.1674-4152.003240
Citation: ZHAO Hao, QI Xueyuan, WANG Junbin, ZHANG Xiaofeng, TAO Lu, YU Liang. Expression and significance of peripheral blood lymphocyte subsets in non-small cell lung cancer[J]. Chinese Journal of General Practice, 2023, 21(11): 1849-1851. doi: 10.16766/j.cnki.issn.1674-4152.003240
shu

Expression and significance of peripheral blood lymphocyte subsets in non-small cell lung cancer

doi: 10.16766/j.cnki.issn.1674-4152.003240
  • 1.

    Central Laboratory, the First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233004, China

Funds:

 202004j07020010

  • Received Date: 2023-06-16
    Available Online: 2024-01-13
    Abstract
  •   Objective  To investigate the dynamic changes and significance of lymphocyte subsets in peripheral blood of non-small cell lung cancer (NSCLC) patients with different pathological types and clinical stages, and to compare the immune status of non-small cell lung cancer patients with healthy people.  Methods  Peripheral blood lymphocyte subsets of non-small cell lung cancer patients admitted to the Respiratory and Oncology Departments of the First Affiliated Hospital of Bengbu Medical College from May 2020 to February 2023 were detected by flow cytometry, including 55 cases of lung squamous cell carcinoma and 49 cases of lung adenocarcinoma, and 25 healthy adults from the health examination center during the same period were screened as controls.  Results  Compared with the control group, the proportions of CD3+ cells and CD4+ cells in NSCLC group were (67.43±9.01) % and (37.34±9.15) %, the ratio of CD4+/CD8+ was 1.57±0.80, which were lower than that in the control group; The proportion of NK cells was (21.22±8.06) %, which was significantly higher than that of the control group; The differences were statistically significant (all P < 0.05). There was no significant difference between squamous cell carcinoma and adenocarcinoma. In Ⅲ - Ⅳ period, the proportion of CD3+ cells and CD4+ cells were (66.33±9.52) % and (36.01±9.44) %, below Ⅰ - Ⅱ period; The proportion of NK cells was (22.81±8.43) %, which was significantly higher than that in stage Ⅰ- Ⅱ; The differences were statistically significant (all P < 0.05).  Conclusion  During the occurrence of NSCLC, the immune function of patients is inhibited, and this inhibition is further aggravated with the progression of the disease. It has certain clinical significance to detect the proportion of T lymphocyte subsets, B cells and NK cells in peripheral blood of NSCLC patients to understand the immune status of the body, evaluate the disease and guide the treatment.

     

    • FullText(HTML)
  • loading
    • References(18)
  • [1]
    蒋一玲, 张传领, 陈承, 等. 贝伐珠单抗联合靶向治疗对EGFR突变型非小细胞肺癌患者的疗效观察[J]. 中华全科医学, 2021, 19(8): 1306-1309. doi: 10.16766/j.cnki.issn.1674-4152.002047

    JIANG Y L, ZHANG C L, CHEN C, et al. Observation of curative effect of bevacizumab combined with targeted treatment of EGFR mutant lung cancer[J]. Chinese Journal of General Practice, 2021, 19(8): 1306-1309. doi: 10.16766/j.cnki.issn.1674-4152.002047
    [2]
    何丽杰, 冯贺强, 褚相南, 等. DC-CIK生物治疗后肺癌患者Pro-GRP和T淋巴细胞亚群对免疫功能评价的临床意义[J]. 中国现代医学杂志, 2018, 28(19): 55-61. doi: 10.3969/j.issn.1005-8982.2018.19.011

    HE L J, FENG H Q, CHU X N, et al. Value of Pro-GRP and T lymphocyte subsets in assessment of immune functions of lung cancer patients after DC-CI biological therapy[J]. China Journal of Modern Medicine, 2018, 28(19): 55-61. doi: 10.3969/j.issn.1005-8982.2018.19.011
    [3]
    ZHANG C T, LU Z M, HUANG H Y. The difference and relationship of CD4+ and CD8+ tumour infiltrating lymphocytes in lung adenocarcinoma[J]. Oncotarget, 2019, 10(13): 1271-1278. doi: 10.18632/oncotarget.26666
    [4]
    KATHRYN J G, JULIE E G. Adaptive immunity, chronic inflammation and the clock[J]. Semin Immunopathol, 2022, 44(2): 209-224. doi: 10.1007/s00281-022-00919-7
    [5]
    贡鸣, 何天宇, 裘敬平, 等. 6种常见肿瘤患者初治时外周血T淋巴细胞亚群数量及临床特征[J]. 中国医科大学学报, 2018, 47(12): 1119-1122. doi: 10.12007/j.issn.0258-4646.2018.12.015

    GONG M, HE T Y, QIU J P, et al. Peripheral blood T-lymphocyte subsets in patients with six kinds of cancer and their clinical characteristics during the initial treatment[J]. Journal of China Medical University, 2018, 47(12): 1119-1122. doi: 10.12007/j.issn.0258-4646.2018.12.015
    [6]
    BARCELLOS-HOFF M H, GULLEY J L. Molecular pathways and mechanisms of TGF-β in cancer therapy[J]. Clin Cancer Res, 2023, 29(11): 2025-2033. doi: 10.1158/1078-0432.CCR-21-3750
    [7]
    李淑勤, 赵树强, 郑丽琴, 等. MicroRNA-425-5p通过靶向Fas信号通路调控肺癌A549细胞增殖、凋亡和转移的机制研究[J]. 中国免疫学杂志, 2022, 38(4): 437-442.

    LI S Q, ZHAO S Q, ZHENG L Q, et al. MicroRNA-425-5p regulates proliferation, apoptosis and metastasis of lung cancer A549 cells by targeting Fas-related signaling pathways[J]. Chinese Journal of Immunology, 2022, 38(4): 437-442.
    [8]
    CHEN T T, CHEN H X, LU W, et al. T lymphocyte subsets and PD-1 expression on lymphocytes in peripheral blood of patients with non-small cell lung cancer[J]. Medicine, 2022, 101(42): e31307. doi: 10.1097/MD.0000000000031307
    [9]
    王琛. 免疫学前沿与转化研究[J]. 药学进展, 2022, 46(8): 561-563.

    WANG S. Frontier and translational research in immunology[J]. Progress in Pharmaceutical Sciences, 2022, 46(8): 561-563.
    [10]
    喻敏, 康晶, 陈志未, 等. NK细胞的生物学特性及其在B细胞淋巴瘤应用中的研究进展[J]. 中国实验血液学杂志, 2020, 28(5): 1782-1786.

    YU M, KANG J, CHEN Z W, et al. Research progress on biological properties of natural killer cells and their application in B cell lymphoma[J]. Journal of Experimental Hematology, 2020, 28(5): 1782-1786.
    [11]
    王春霞, 辛丽亚, 张桂红, 等. 肺癌患者化疗前后外周血T淋巴细胞亚群及NK细胞的变化[J]. 中华肿瘤防治杂志, 2018, 6(25): 48-49.

    WANG C X, XIN L Y, ZHANG G H, et al. Variation of blood T lymphocyte subsets and NK cells before and after chemotherapy of the lung cancer in patients with peripheral[J]. Chinese Journal of Cancer Prevention and Treatment, 2018, 6(25): 48-49.
    [12]
    李爱杰, 刘超, 贺科文, 等. 非小细胞肺癌患者外周血淋巴细胞亚群水平检测临床意义[J]. 中华肿瘤防治杂志, 2020, 27(9): 740-744.

    LI A J, LIU C, HE K W, et al. Expression of peripheral lymphocytes subsets and its clinical significance in patients with non-small cell lung cancer[J]. Chinese Journal of Cancer Prevention and Treatment, 2020, 27(9): 740-744.
    [13]
    王健, 蒋国军, 戴婷, 等. 外周血淋巴细胞亚群和NK细胞在鉴别良恶性肺磨玻璃结节中的意义[J]. 南京医科大学学报, 2019, 39(8): 1217-1219.

    WANG J, JIANG G J, DAI T, et al. Significance of peripheral blood lymphocyte subsets and NK cells in differentiating benign and malignant pulmonary ground glass nodules[J]. Journal of Nanjing Medical University, 2019, 39(8): 1217-1219.
    [14]
    PENDE D, FALCO M, VITALE M, et al. Killer Ig-like receptors (KIRs): their role in NK cell modulation and developments leading to their clinical exploitation[J]. Front Immunol, 2019, 28(10): 1179.
    [15]
    高斌成. 非小细胞肺癌外周血CD3+、CD4+等T淋巴细胞亚群水平及意义[J]. 临床肺科杂志, 2018, 23(1): 138-141.

    GAO B C. Expression and significance of CD3+, CD4+ T lymphocyte subsets in patients with non-small cell lung cancer[J]. Journal of Clinical Pulmonary Medicine, 2018, 23(1): 138-141.
    [16]
    牛越, 石晓宇. 外周血淋巴细胞亚群检测在肺癌患者临床评估及辅助治疗中的意义[J]. 实用癌症杂志, 2019, 34(5): 785-787.

    NIU Y, SHI X Y. Significance of detection of peripheral bloodlymphocyte subsets in clinical evaluation and adjuvant treatment of patients with lung cancer[J]. The Practical Journal of Cancer, 2019, 34(5): 785-787.
    [17]
    张楠, 周晓燕, 卞涛. 外周血T淋巴细胞亚群检测在非小细胞肺癌中的临床意义[J]. 当代医学, 2020, 26(22): 80-82.

    ZHANG N, ZHOU X Y, BIAN T. Clinical significance of peripheral blood T-lymphocyte subsets determination in non-small cell lung cancer[J]. Contemporary Medicine, 2020, 26(22): 80-82.
    [18]
    SOPHIE S, ALI B D, PHILIPP L, et al. Elevated levels of circulating Hsp70 and an increased prevalence of CD94+/CD69+ NK cells is predictive for advanced stage non-small cell lung cancer[J]. Cancers, 2022, 14(22): 5701-5713.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(6)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (276) PDF downloads(21) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return